Patient response to a therapeutic or biosimilar is both a key indicator for analysing a drug’s suitability for market approval and for directing a patient’s therapy pathway. One such solution to assessing patient response is with the use of a complementary near-patient test, also known as a point-of-care (POC) test.
On this page we discuss the use of lateral flow technology as a near-patient testing solution: pregnancy-test-style technology that can be used across multiple industry sectors and in multiple testing scenarios.
To achieve patient-centric growth ambitions, therapeutics need to fill a gap in the market, or meet or exceed market expectations. Here is how near-patient testing can meet this requirement:
Monitoring a patient’s response in order to direct a patient’s therapy pathway, or using a point-of-care approach to allow early diagnosis will inevitably create different testing scenarios and requirements, which can create pros and cons for both patient and clinician.
For example, there may be a requirement to monitor multiple drug activity markers, patients may need regular testing or a patient’s round trip to a clinic for routine testing could be lengthy and costly.
The following capabilities highlights how lateral flow technology can cope with various testing scenarios.
Lateral flow technology can be:
Abingdon Health specialises in the development, manufacture and commercialisation of qualitative, semi- and fully-quantitative near-patient testing solutions.
As we have launched our own point-of-care test for haematology-oncology and already work with key global pharmaceutical companies, Abingdon Health’s experience offers companies a de-risked approach to introducing a near-patient testing solution for pharma.
Our services and assistance include:
Download a copy of our brochure to see how Abingdon Health can aid the development of a near-patient testing solution to help your therapeutic or biosimilar standout from the crowd.
Topics covered in the brochure include:
Tel: +44 (0) 1904 406080
© Abingdon Health 2019